Review of the safety and efficacy of voriconazole

Expert Opinion on Investigational Drugs

Volumn 11, Issue 3, 2002, Pages 409-429

  Hoffman, Holly L ^a   Rathbun, R Chris ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antifungal; Triazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; LATANOPROST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PHENYTOIN; PLACEBO; PREDNISOLONE; PYRROLE DERIVATIVE; RIFABUTIN; RIFAMYCIN; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE; WARFARIN; PYRIMIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BLASTOMYCES DERMATITIDIS; CANDIDA; COCCIDIOIDES IMMITIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GRAPEFRUIT JUICE; HALLUCINATION; HEADACHE; HISTOPLASMA CAPSULATUM; HUMAN; LIVER DYSFUNCTION; MOULD; MYCOSIS; NONHUMAN; PHOTOPHOBIA; SCEDOSPORIUM APIOSPERMUM; VISUAL DISORDER; VISUAL IMPAIRMENT; ANIMAL; DEUTEROMYCETES; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MITOSPORIC FUNGI; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 0036198329     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.3.409     Document Type: Article

References (134)

1. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infection: Discovery and antifungal properties
2. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infection: Pharmacokinetics in man
3. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
4. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
5. Drug interactions between voriconazole and phenytoin
6. Effect of omeprazole on the pharmacokinetics of voriconazole
7. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole
8. Pharmacokinetics and safety of oral voriconazole in patients at risk of fungal infections: A dose escalation study
9. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infection: Disposition in animals
10. Invasive aspergillosis caused by Aspergillus ustus: Case report and review
11. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infection: Disposition in man
12. Voriconazole does not affect the pharmacokinetics of digoxin
13. The effect of voriconazole on the pharmacokinetics of cyclosporin
14. Voriconazole potentiates warfarin-induced prolongation of prothrombin time
15. The pharmacokinetics of voriconazole and its effect on prednisolone disposition
16. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
17. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infection: Clinical efficacy in chronic invasive aspergillosis
18. UK-109,496, A novel wide-spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
19. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial
20. Visual effects with voriconazole
21. The pharmacokinetics and safety of sulphobutylether-b-cyclodextrin
22. Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole
23. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy
24. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole
25. Investigation of the relationship between plasma voriconazole concentrations and liver function tests abnormalities in therapeutic trials
26. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment
27. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
28. First-pass metabolism of cyclosporin by the gut
29. Effect of voriconazole on the pharmacokinetics of tacrolimus
30. Voriconazole inhibition of tacrolimus metabolism after liver transplantation and in human liver microsomes
31. Drug interactions of HIV protease inhibitors
32. No significant pharmacokinetic interactions between voriconazole and indinavir
33. Derangement of warfarin anticoagulation by miconazole oral gel
34. Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies
35. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
36. Digoxin-itraconazole interaction
37. Interaction between itraconazole and digoxin
38. Interaction of itraconazole and digoxin
39. Voriconazole does not affect the pharmacokinetics of mycophenolic acid
40. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance
41. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine
42. Uk-109,496, a novel wide-spectrum triazole derivative for the treatment of fungal infections: Pre-clinical pharmackinetics
43. Effect of grapefruit juice on serum voriconazole concentrations in the mouse
44. An overview of nosocomial infections, including the role of the microbiology laboratory
45. Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy
46. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
47. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
48. In vitro activity of voriconazole against Candida species
49. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
50. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis
51. In vitro activities of voriconazole (UK-109,496) against fluconazole- susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
52. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading
53. Evaluation of voriconazole pharmacodynamics using time-kill methodology
54. Activity of voriconazole: Post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes
55. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model
56. Efficacy of voriconazole in a guinea pig model of systemic C. albicans infection caused by isolates with elevated fluconazole MICs
57. Efficacy of voriconazole in the treatment of hematogenously disseminated Candida glabrata in a neutropenic guinea pig model
58. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS
59. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
60. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
61. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole
62. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans
63. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Cryptococcus
64. Invasive central nervous system aspergillosis: Cure with liposomal amphotericin B, itraconazole, and radical surgery-case report and review of the literature
65. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997
66. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
67. Therapeutic outcome in invasive aspergillosis
68. In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
69. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
70. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
71. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
72. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
73. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
74. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
75. In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates
76. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin
77. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
78. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole
79. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison of voriconazole
80. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity in experimental infections with Aspergillus
81. Organism-dependent fungicidal activities of azoles
82. UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: Synthesis and SAR
83. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
84. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis
85. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis
86. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
87. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
88. Voriconazole for salvage therapy of fungal infection in patients with hematological malignancies and stem cell transplantation
89. Open randomized comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis
90. Voriconazole for salvage treatment of invasive aspergillosis
91. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: Cure with voriconazole
92. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation
93. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis
94. Aspergillus meningitis: Diagnosis by non-culture-based microbiological methods and management
95. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
96. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
97. Evaluation of voriconazole efficacy in the treatment of murine fusariosis
98. Voriconazole for the treatment of resistant and rare fungal pathogens
99. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis
100. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
101. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
102. Voriconazole for the treatment of S. apiospermum and S. prolificans infection
103. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis
104. In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi
105. In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs
106. In vitro activity of voriconazole against selected fungi
107. Evaluation of combination agents against zygomycetes
108. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
109. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
110. Potentiation of voriconazole ocular penetration by topical latanoprost co-administration
111. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro
112. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model
113. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albican's: Effect of concentration and exposure time
114. S Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration
115. Efficacy and safety of voriconazole in the treatment of invasive fungal infection in children
116. Effect of voriconazole on the pharmackinetics of omeprazole
117. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies
118. Voriconazole against fluconazole-susceptible and resistant candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole
119. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
120. In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
121. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
122. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
123. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media
124. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
125. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents
126. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
127. Antifungal susceptibility of yeasts responsible for bloodstream infections
128. In vitro evaluation of voriconazole against some clinically important fungi
129. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
130. In vitro activities of four novel triazoles against Scedosporium spp
131. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains
132. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method
133. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine